Publications

  • Journal Papers
  • Authored Books

Total 100 publications (JNCI 1, J Clin Invest 2, Cancer Res 9, J Immunol 2, JBC 2);

  1. Zhang J, Pugh TD, Stebler, B, Ershler WB, Keller ET. Orc  hiectomy increases bone-marrow interleukin-6 levels in mice.  Calcif Tiss Int. 62:219-226, 1998. 
  2. Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through interleukin-6 in mice.  J Clin Invest. 106:887-895, 2000. 
  3. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001. 
  4. Yao Z, Zhang J, Dai J, Keller ET. Ethanol activates NFkB DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells.  Bone 28:167-173, 2001.
  5. Keller ET, Zhang J, Yao Z, Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatta) model of menopause.  J Repro Immunol.  50:41-55, 2001
  6. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.
  7. Keller ET, Zhang J, Cooper C.R, Smith P.C, McCauley L.K, Pienta K.J, Taichman R S. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Reviews. 20:333-349, 2001. 
  8. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice.  J Bone Miner Res 17:1256-1263, 2002. 
  9. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003 
  10. Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer cell proliferation and PSA expression through interleukin-6-induced activation of the androgen receptor. Clin Exp Metastasis. 21 (5): 399-408, 2004
  11. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D'Silva NJ, McCauley LK. Impact of the mitogen-activated protein kinase (MAPK) pathway on parathyroid hormone related protein actions in osteoblasts.  J Biol Chem.  279(28): 29121-9, 2004 
  12. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. 59:360-9, 2004 
  13. Zhang J, Lu Y, O’Brein C, Dai J, Qi W, Hall D, Yao Z, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging.  Experimental Gerontology. 39:239-247, 2004 
  14. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res. 64:994-9, 2004 
  15. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res. 65 (23):10921-9. 2005 
  16. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 65(18): 8274-85, 2005 
  17. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis. 8(3): 253-9, 2005 
  18. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. 66:1311-8, 2006
  19. Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET.Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 66(6):3087-95, 2006 
  20. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007 
  21. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*. CCR2 expression correlates with prostate cancer p J Cell Biochem. 101:676-685, 2007 
  22. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment.  Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007
  23. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007 
  24. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008
  25. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008 
  26. Yu S, Jiang Y, Galson DL, Luo M, Lai Y, Lu Y, Ouyang H, Zhang J, Xiao G. General transcription factor IIA-gamma increases osteoblast-specific Osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2.  J Biol Chem, 283(9):5542-53, 2008 
  27. Lee J, Gong H, Khadem S, Lu Y, Zhang J, Xie W. Androgen deprivation by activating the nuclear receptor LXR. Endocrinology, 149(8):3778-88, 2008 
  28. Yu S, Franceschi R, Luo M, Zhang X, Jiang D, Lai Y, Jiang Yu, Ouyang H, Zhang J, Xiao G. Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression.  Endocrinology, 149(4):1960-8, 2008
  29. Singha UK, Jiang Y, Yu SB, Luo M, Lu Y, Zhang J, and Xiao G. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse marrow stromal cells. J Cell Biochem, 103(2): 434-46, 2008
  30. Wang J, Lu Y, Wang J, Koch A, Zhang J, Taichman R. CXCR6 induced prostate cancer progression by the Akt/mTOR signaling pathway. Cancer Res. 68(24):10367-76, 2008 
  31. Liu Y, Yuan Y, Li Y, Zhang J, Xiao G, Vodovotz Y, Billiar TR, Wilson M, and Fan J. Interacting neuro-endocrine, innate, and acquired immune pathways regulate neutrophil mobilization from bone marrow following hemorrhagic shock.  J of Immunol, 182(1):572-80,2009
  32. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009 
  33. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo.  Neoplasia, 11(3):228-236, 2009 
  34. Su D, Coudriet GM, Kim DH, Lu Y, Perdomo G, Qu S, Slusher S, Tse HM, Piganelli J, Nick Giannoukakis N, Zhang J and Dong HH. FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages, Diabetes, 58(11):2624-33. 2009
  35. Li Y, Xiang M, Yuan Y, Xiao G, Zhang J, Jiang Y, Vodovotz Y, Billiar TR, Wilson MA, Fan J. Hemorrhagic Shock Augments Lung Endothelial Cell Activation: Role of Temporal Alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol. Oct 14, 2009 
  36. Yu S, Franceschi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Patrene K, Hankenson K, Roodman GD, Xiao G. Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One. Oct 23;4(10):e7583, 2009 
  37. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010 
  38. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010 
  39. Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, Keller ET. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res. 70 (12):5014-23, 2010 
  40. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011
  41. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. Dec;29(4):709-22, 2010
  42. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic.  Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
  43. Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa Tumor Microenvironment. Cancer Microenviron. 2011 Dec;4(3):283-97.
  44. Zheng J, Wang J, Sun X, Hao M, Ding T, Xiong D, Wang X, Zhu Y, Xiao G, Cheng G, Zhao M, Zhang J, and Wang J. HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification. Clin Cancer Res; 2013, 19(6); 1400–10. 
  45. Zhang H, Yu C, Dai J, Keller JM, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-Catenin activation of the DKK1 promoter in prostate cancer. 2014, 8;33(19):2464-77 
  46. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*,Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014
  47. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86
  48. Escara-Wilke J, Keller J, Ignatoski K, Dai J, Mozokami A, Shelley G, Zhang J, Yeung M, Yeung K, Keller E. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increase metastasis in a murine genetic model of prostate cancer. 2014 Oct 18. doi: 10.1002/pros.22915
  49. Guo H, Zhou X, Lu Y, Xie L, Chen Q, Keller ET, Liu Q, Zhou Q* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294 
  50. Zhu Y, Zou C, Zhang Z, Qian CN , Yang X, Shi J, Xia Y,  Zhang J*, Lu Y*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression.  Tumor Biology, 2015, 36(11):8811-8. doi: 10.1007/s13277-015-3595-8. 
  51. He S , Lu Y,  Liu X,  Huang X,  Keller E, Qian CN *,  Zhang  J *. Wnt3a: function and implication in cancer.  Chinese Journal of Cancer, 2015, 34(3):50. DOI: 10.1186/s40880-015-0052-4 
  52. Chen Z, Wang S, Zou C, Fu L, Wang B, An J, Song G, Wu J, Tang X, Li M, Zhang J, Yue F, Zheng C, Chan P, and Zhang Alex Y.  Autologous iPSC-derived dopamine neuron transplantation in a nonhuman primate Parkinson's disease model. Cell Discovery, 2015, May 26;1:15012. doi: 10.1038/celldisc.2015.12. eCollection 2015.
  53. Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, Dhanasekaran S, Wang Z, Kalyana-Sundaram S, Balbin A, Shukla S, Lu Y, Lin J, Reddy R, Carrott P, Lynch W, Chang A, Chinnaiyan A, Beer DG*, Zhang J*, Chen G *.  Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer.Oncotarget, 2016, 7(10):11487-99 
  54. Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, Liu X, Tan J, Hu L, Lu Y*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.
  55. Yang Y, Lu Y, Wang L, Mizokami A, Keller ET, Zhang J*, Fu J*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.
  56. Liu Y, Chai Y, Zhang J*, and Tang J*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8,2016.
  57. Chen Q, Qin S, Liu Y, Hong M, Qian CN, Keller ET, Zhang J,  Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.
  58. Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, Zhang J* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.
  59. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.
  60. Wang W, Wang L, Mizokami A, Shi J, Zou C, Dai J, Keller ET, Lu Y* and Zhang J*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35
  61. Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK. and Keller ET. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29
  62. Zou C, Lu Y, Teng X, Wang S, Sun X, Huang F, Shu G, Huang X, Guo H, Chen Z, Zhang J, Zhang YA. In vivo MR imaging of intrahepatic autologous transplantation of insulin-producing cells derived from pancreatic progenitor cells to diabetic monkey Sci. Rep. 2017 7(1):2505.
  63. Meng J, Wang L, Zou C, Dai S, Zhang J *, Lu Y*. C10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance. Med Sci Monit 2017; 23:5176-5183. DOI: 10.12659/MSM.906680.
  64. Pascal LE, Masoodi KZ, Liu J, Qiu X, Song Q, Wang Y, Zang Y, Yang T, Wang Y, Rigatti LH, Chandran U, Colli LM, Vencio RZN, Lu Y, Zhang J, Wang Z. Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol. 2017 Nov;235(2):123-136. doi: 10.1530/JOE-17-0112.
  65. Haibo Tong, Chunlin Zou, Siyuan Qin, Jie Meng, Evan T Keller, Jian Zhang* and Yi Lu*. Prostate cancer tends to metastasize in bone-mimicking microenvironment via activation of the NF-κB pathway. Journal of Biomedical Research, 2018, 32(5):343-53.
  66. Xia Y, Liu X, Zou C, Feng S, Guo H, Yang Y, Lei Y, Zhang J*, and Lu Y*. Garcinone C exerts antitumor activity by modulating the expression of ATR/Stat3/4E‑BP1 in nasopharyngeal carcinoma cells. Oncology Reports, 2018, 39:1485-93.
  67. Junlin Shi, Lihui Wang, Chunlin Zou, Yudui Xia, Siyuan Qin, Evan Keller, Atsushi Mizokami, Jian Zhang*, Yi Lu*. Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. Oncotarget, 2018, 9(10):9206-18.
  68. Wang W, Yang X, Dai J, Lu Y, Zhang J, and Keller E*. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene, 2019, 38(23):4540-45559. Doi: 10.1038/s41388-019-0736-3
  69. Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G. LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma.  Aging-US. 2019 May 13;11(9):2812-2821. doi: 10.18632/aging.101953.
  70. Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y*, Zhang J*. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. J Cancer Res Clin Oncol. 2019 Jun 6. 145:1999-2012.  doi: 10.1007/s00432-019-02950-y.
  71. Guo H, Wang F, Diao Y, Zhang Z, Chen Q, Qian CN, Keller ET, Zhang J*, Lu Y*. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA. Molecular Carcinogenesis, 2019, 58:1886-1896.
  72. Yun C, Chang M, Hou G, Lan T, Yuan H, Su Z, Zhu D, Liang W, Li Q, Zhu H, Zhang J, Lu Y*, Deng J*, Guo H*. Mangiferin suppresses allergic asthma symptoms by decreased Th9 and Th17 responses and increased Treg response. Molecular Immunology. 2019, 114:233-242.
  1. Yung R, Keller ET, Zhang J. Aging and Immunity.  In: Xi H-Z, ed.  Chinese Textbook of Geriatrics and Gerontology, 2nd Ed.  Publisher of Peoples Public Health, China, 2001 
  2. Yung R, Zhang J. Aging and bone diseases.  In: Xi H-Z, ed.  Chinese Textbook of Geriatrics and Gerontology, 2nd Ed.  Publisher of Peoples Public Health, China, 2001 
  3. Brown J, Zhang J, Keller ET. OPG, RANKL and RANK in cancer metastasis. In: Keller ET and Chung WK, ed. The Biology of Bone Metastases. Kluwer Academic Publishers, 2004
  4. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic.  Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.
  5. Guo H, Lu Y, and Zhang J. Recent Progress in Translational Medicine Research on Tumor Markers. 《中国医学科技发展报告》, Science Press, 2014

Copyright © 2018 All Rights Reserved.